The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Claim CLM-00001. 1. A method of treating seizures in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments.
Claim CLM-00013. 13. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day.
Claim CLM-00014. 14. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day.
Claim CLM-00016. 16. A method of treating seizures in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments.
